Stock Market Reviews

ADGM (Adagio Medical Holdings, Inc.) News

Get the latest news, insights, and market updates on ADGM (Adagio Medical Holdings, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Adagio Medical Reports Third Quarter 2025 Results
  LAGUNA HILLS, Calif., November 12, 2025--Adagio Medical Holdings, Inc (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the third quarter ended September 30, 2025.
  Nov 12, 2025 - $ADGM
• Adagio Medical to Present at the Piper Sandler 37th Annual Healthcare Conference
  LAGUNA HILLS, Calif., November 05, 2025--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that management will be presenting at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025, at 10:30 a.m. ET at the Lotte Palace in New York, NY.
  Nov 5, 2025 - $ADGM
• Adagio Medical Closes Financing of $19 Million Upfront; Positions Company to Advance Purpose-Built Technology for Treatment of Ventricular Tachycardia
  LAGUNA HILLS, Calif., October 20, 2025--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the closing of its previously announced private placement (https://investors.adagiomedical.com/news-releases/news-release-details/adagio-medical-announces-pricing-50-million-private-placement), led by existing investors and new healthcare-dedicated institutional investors.
  Oct 20, 2025 - $ADGM
• Adagio Medical Announces Pricing of up to $50 Million Private Placement of Securities
  LAGUNA HILLS, Calif., October 15, 2025--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or the "Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that it has entered into a securities purchase agreement with certain accredited investors to purchase shares of its common stock (or pre-funded warrants in lieu thereof), and accompanying common warrants ("Warrants") that is expected to result in approximately $19 million
  Oct 15, 2025 - $ADGM
• Adagio Medical Unveils Preliminary Acute Results from FULCRUM-VT U.S. Pivotal Study in Late Breaking Session at VT Symposium
  LAGUNA HILLS, Calif., October 10, 2025--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced preliminary acute (within 7 days) safety and efficacy results from the Adagio’s FULCRUM-VT Study evaluating Ultralow Temperature Cryoablation ("ULTC") for the treatment of Sustained Monomorphic Ventricular Tachycardia ("SMVT") in patients with both ischemic and nonischemic
  Oct 10, 2025 - $ADGM
• Adagio Medical, Inc. Announces Completion of Enrollment for FULCRUM-VT Pivotal Clinical Trial Evaluating Ultra-Low Temperature Cryoablation for Ventricular Tachycardia
  LAGUNA HILLS, Calif., October 01, 2025--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the completion of enrollment of the FULCRUM-VT Pivotal U.S. Food and Drug Administration ("FDA") Investigational Device Exemption ("IDE") study evaluating the Company’s vCLASTM Cryoablation System ("vCLAS" or "vCLAS System") for ablation of monomorphic ventricular tachycard
  Oct 1, 2025 - $ADGM
• Adagio Medical FULCRUM-VT U.S. Pivotal Study Acute Results to be Presented in Late-Breaking Session at VT Symposium
  LAGUNA HILLS, Calif., September 18, 2025--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that acute results from the Company’s FULCRUM-VT U.S. pivotal study have been accepted for presentation in a late-breaking clinical science session at The 20th Annual International Symposium on Ventricular Arrhythmias, being held from October 10- 11, 2025 at the Philadelp
  Sep 18, 2025 - $ADGM
• Adagio Medical Expands Chief Business Officer Deborah Kaster’s Role to Include Chief Financial Officer Responsibilities
  LAGUNA HILLS, Calif., September 08, 2025--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that the Company’s Chief Business Officer, Deborah Kaster’s, responsibilities have been expanded to include the role of Chief Financial Officer, effective September 5, 2025. Ms. Kaster succeeds Dan George, who served as the Company’s interim Chief Financial Officer since
  Sep 8, 2025 - $ADGM
• Adagio Medical Reports Second Quarter 2025 Results
  LAGUNA HILLS, Calif., August 13, 2025--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the second quarter ended June 30, 2025.
  Aug 13, 2025 - $ADGM
• Adagio Medical Reports First Quarter 2025 Results
  LAGUNA HILLS, Calif., May 15, 2025--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the first quarter ended March 31, 2025.
  May 15, 2025 - $ADGM